|
HY-P7539-50ug
|
MedChemexpress LLC
|
APT-1/LYPLA1, Human (His)
|
|
|
|
|
HY-P1695-1mg
|
MedChemexpress LLC
|
Cinnamycin [CAS 110655-58-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-B0304A-100mg
|
MedChemexpress LLC
|
Dapoxetine (hydrochloride) [CAS 129938-20-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-B0304A-50mg
|
MedChemexpress LLC
|
Dapoxetine (hydrochloride) [CAS 129938-20-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-B0304A-1mL
|
MedChemexpress LLC
|
Dapoxetine (hydrochloride) [CAS 129938-20-1] (10mM in DMSO)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-W111226-100mg
|
MedChemexpress LLC
|
Fmoc-His(3-Me)-OH [CAS 252049-16-4]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-W111226-250mg
|
MedChemexpress LLC
|
Fmoc-His(3-Me)-OH [CAS 252049-16-4]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-W111226-50mg
|
MedChemexpress LLC
|
Fmoc-His(3-Me)-OH [CAS 252049-16-4]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-13682B-1mg
|
MedChemexpress LLC
|
MifaMu rtide (sodium) [CAS 90825-43-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13682B-10mg
|
MedChemexpress LLC
|
MifaMu rtide (sodium) [CAS 90825-43-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13682B-5mg
|
MedChemexpress LLC
|
MifaMu rtide (sodium) [CAS 90825-43-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13682C-1mg
|
MedChemexpress LLC
|
MifaMu rtide (TFA)
|
|
COVID-19-immunoregulation
|
|
|
HY-13682C-10mg
|
MedChemexpress LLC
|
MifaMu rtide (TFA)
|
|
COVID-19-immunoregulation
|
|
|
HY-13682C-5mg
|
MedChemexpress LLC
|
MifaMu rtide (TFA)
|
|
COVID-19-immunoregulation
|
|
|
HY-13682-1mg
|
MedChemexpress LLC
|
MifaMu rtide [CAS 83461-56-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13682-10mg
|
MedChemexpress LLC
|
MifaMu rtide [CAS 83461-56-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13682-5mg
|
MedChemexpress LLC
|
MifaMu rtide [CAS 83461-56-7]
|
|
Cancer-programmed cell death
|
|
